A Pharmaceutical from Coimbra has made a strong investment in the generic market and exports 70% of its products. But research is also one of its goals.
Through generics, we intend to reach innovative medicines”, says Paulo Barradas Rebelo. This is the reason why, besides indoor investigation, Bluepharma is working with three spin-offs from academia– Technophage from Lisbon and Luzitin and TREAT U from Coimbra – pursuing a dream: “We have the ambition of contributing for the creation of a novel medicine, namely in the oncology field. This is our goal.”
